The Cribsiders podcast

#102: RSV Immunizations

January 31, 2024 | By

Audio

Summary:

The Curbsiders and Cribsiders are back with a very special Med-Peds collaboration on RSV immunizations! Dr. Buddy Creech, Pediatric Infectious Disease at Vanderbilt, walks us through these breakthrough “vaccines” for both adults and kids. He teaches us about their mechanisms of action, eligibility criteria, and why it’s been so challenging to find doses this season. Get ready for your next shot of fun!


Correction to earlier infographic

RSV Immunization Show Notes and Pearls

RSV Demographics and Public Health

  1. Respiratory Syncytial Virus (RSV) shows a U-shaped curve in morbidity and mortality, impacting both infants (<9 months) and older individuals (60yo+).
  2. RSV is the number one cause of hospitalization among pediatric patients.
  3. 6% of hospitalization for lower respiratory tract infections are related to RSV.
  4. Protecting adult infections may have public health implications in limiting transmission to cause pediatric infections. 

Pediatric Immunization

  1. Synagis (Pavilizumab) previously was only option
  2. Synagis limitations included short half-life (20d) requiring multiple doses.
  3. Beyfortus (Nirsevimab) is new monoclonal antibody that targets the pre-fusion form of the RSV F protein.
  4. Nirsevimab offers longer protection (5 months) with a single dose. 
  5. It’s now recommended for infants under 8 months and high-risk children up to 19 months.
  6. Unlike Pavilizumab, Nirsevimab also targets the pre-fusion F protein on the surface of the virus before it docks with the cell. 
  7. Nirsevimab is associated with a 75% decrease in all medically attended lower respiratory tract infections (with a statistically insignificant trend to decrease in hospitalizations by 60%.) – MELODY Trial
  8. Dosing by weight: <5kg = 50mg; >5kg =100mg

Adult Immunizations

  1. GSK Arexy vaccine has adjuvant which may make vaccine more potent, and certainly makes side effects more potent.
  2. Pfizer Abrysvo does not have an adjuvant and has been shown to be safe in pregnancy. 
  3. Both vaccines show ~75% vaccine efficacy in reducing two or more symptoms of RSV in the first three months after immunization
  4. There was a theoretical concern of giving adjuvant GSK Arexy with the influenza vaccine, but a recent trial showed this to be safe. (Lancet)

Goal

Listeners will explain the basic differences between the three new RSV immunizations. 

Learning Objectives

After listening to this episode listeners will…  

  1. Describe the epidemiology of RSV
  2. Discuss the three new RSV immunizations
  3. Identify the purpose of an adjuvant in immunization
  4. List the indications for these immunizations
  5. Feel comfortable counseling patients these immunizations

Disclosures

Dr Creech reports no relevant financial disclosures. The Cribsiders report no relevant financial disclosures. 

Citation

Creech B, Masur S, Williams P, Chiu C, Berk J. “102: RSV Immunizations”. The Cribsiders Pediatric Podcast. https:/www.thecribsiders.com/ January 31, 2024.


 

Episode Sponsors

Factor

Factor, the chef-crafted, dietitian-approved meal delivery service, is offering Cribsiders listeners 50% off by going to factormeals.com/cribsiders50

Freed AI

Freed, the new AI scribe that listens, transcribes, and writes medical documentation for you, is available for Cribsiders listeners at a discount. Go to GetFreed.AI and use code CRIB50 to get $50 off

Episode Credits

Producer, Writer, Infographic: Justin Berk, MD
Showrunner: Sam Masur, MD
Cover Art: Chris Chiu MD
Hosts: Justin Berk, MD Chris Chiu MD, Paul Williams MD
Editor:Clair Morgan of nodderly.com
Guest(s): Buddy Creech, MD

CME Partner

vcuhealth

The Cribsiders are partnering with VCU Health Continuing Education to offer FREE continuing education credits for physicians and other healthcare professionals. Visit cribsiders.vcuhealth.org and search for this episode to claim credit.

Contact Us

Got feedback? Suggest a Cribsiders topic. Recommend a guest. Tell us what you think.

Contact Us

We love hearing from you.

Notice

We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes as specified in the cookie policy. Denying consent may make related features unavailable.

Close this notice to consent.